Increasing incidence of brain metastasis in patients with advanced Hepatocellular carcinoma in the era of Antiangiogenic targeted therapy

Oncologist

Volumn 16, Issue 1, 2011, Pages 82-86

  Shao, Yu Yun ^a,b   Lu, Li Chun ^b   Cheng, Ann Lii ^a,b,c   Hsu, Chih Hung ^b,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b Departments of Oncology   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Antiangiogenic therapy; Brain metastasis; Hepatocellular carcinoma

Indexed keywords

BEVACIZUMAB; CAPECITABINE; ERLOTINIB; SORAFENIB; SUNITINIB; THALIDOMIDE; UFT;

ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; BRAIN SURGERY; CANCER INCIDENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LUNG METASTASIS; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOSURGERY; RETROSPECTIVE STUDY; SURVIVAL TIME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; BRAIN NEOPLASMS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; RETROSPECTIVE STUDIES;

EID: 79952612562     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0272     Document Type: Article

References (22)

1. Murakami K, Nawano S, Moriyama N et al. Intracranial metastases of hepatocellular carcinoma: CT and MRI. Neuroradiology 1996;38(suppl 1): S31-S35.
2. Kim M, Na DL, Park SH et al. Nervous system involvement by metastatic hepatocellular carcinoma. J Neurooncol 1998;36:85-90.
3. Chen SF, Tsai NW, Lui CC et al. Hepatocellular carcinoma presenting as nervous system involvement. Eur J Neurol 2007;14:408-412.
4. Choi HJ, Cho BC, Sohn JH et al. Brain metastases from hepatocellular carcinoma: Prognostic factors and outcome: Brain metastasis from HCC. J Neurooncol 2009;91:307-313.
5. Chang L, Chen YL, Kao MC. Intracranial metastasis of hepatocellular carcinoma:Review of 45 cases. Surg Neurol 2004;62:172-177.
6. Hsieh MJ, Lu CH, Tsai NW et al. Prediction, clinical characteristics and prognosis of intracerebral hemorrhage in hepatocellular carcinoma patients with intracerebral metastasis. J Clin Neurosci 2009;16:394-398.
7. Yen FS, Wu JC, Lai CR et al. Clinical and radiological pictures of hepatocellular carcinoma with intracranial metastasis. J Gastroenterol Hepatol 1995;10:413-418.
8. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
9. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
10. Zhu AX. Beyond sorafenib: Novel targeted therapies for advanced hepatocellular carcinoma. Expert Opin Investig Drugs 2010;19:663-672.
11. Hsu C, Chang D, Lin Z et al. Thalidomide plus tegafur/uracil for the treatment of advanced/metastatic hepatocellular carcinoma (HCC): A phase II single-arm study. J Clin Oncol 2008;26(15 suppl):15598.
12. Hsu CH, Shen YC, Lin ZZ et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol 2010;53:126-131.
13. Hsu CH, Yang TS, Hsu C et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010;102:981-986.
14. Shao YY, Lin ZZ, Hsu C et al. Early alpha-fetoprotein response predictstreatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010;116:4590-4596.
15. Hsu C, Kang Y, Yang T et al. A phase II study of bevacizumab (B) and erlotinib (E) in combination for Asian patients (pts) with advanced/metastatic hepatocellular carcinoma (HCC): An interim safety report. J Clin Oncol 2009;27(15 suppl):4585.
16. Clayton AJ, Danson S, Jolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91:639-643.
17. Sundermeyer ML, Meropol NJ, Rogatko A et al. Changing patterns of boneand brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 2005;5:108-113.
18. Weil RJ, Palmieri DC, Bronder JL et al. Breast cancer metastasis to the central nervous system. Am J Pathol 2005;167:913-920.
19. Chen AM, Jahan TM, Jablons DM et al. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: Clinical implications for the subsequent management of the brain. Cancer 2007;109:1668-1675.
20. Ricciardi S, de Marinis F. Multimodality management of non-small cell lung cancer patients with brain metastases. Curr Opin Oncol 2010;22:86-93.
21. Pàez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
22. Ebos JM, Lee CR, Cruz-Munoz W.et al. Accelerated metastasis after shortterm treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009;15:232-239.